181 related articles for article (PubMed ID: 38752780)
1. Current scenario of fused pyrimidines with in vivo anticancer therapeutic potential.
Xu Z; Wang L; Hu H
Arch Pharm (Weinheim); 2024 May; ():e202400202. PubMed ID: 38752780
[TBL] [Abstract][Full Text] [Related]
2. Current scenario of pyrazole hybrids with in vivo therapeutic potential against cancers.
Xu Z; Zhuang Y; Chen Q
Eur J Med Chem; 2023 Sep; 257():115495. PubMed ID: 37209450
[TBL] [Abstract][Full Text] [Related]
3. FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
Wang S; Yuan XH; Wang SQ; Zhao W; Chen XB; Yu B
Eur J Med Chem; 2021 Mar; 214():113218. PubMed ID: 33540357
[TBL] [Abstract][Full Text] [Related]
4. Benzimidazole hybrids as anticancer drugs: An updated review on anticancer properties, structure-activity relationship, and mechanisms of action (2019-2021).
Feng LS; Su WQ; Cheng JB; Xiao T; Li HZ; Chen DA; Zhang ZL
Arch Pharm (Weinheim); 2022 Jun; 355(6):e2200051. PubMed ID: 35385159
[TBL] [Abstract][Full Text] [Related]
5. Roles of Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Anticancer Agents.
Prachayasittikul S; Pingaew R; Worachartcheewan A; Sinthupoom N; Prachayasittikul V; Ruchirawat S; Prachayasittikul V
Mini Rev Med Chem; 2017; 17(10):869-901. PubMed ID: 27670581
[TBL] [Abstract][Full Text] [Related]
6. Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery.
Li W; Zhang J; Wang M; Dong R; Zhou X; Zheng X; Sun L
Curr Top Med Chem; 2022 Mar; 22(4):284-304. PubMed ID: 35021973
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities.
Yang M; Liu H; Zhang Y; Wang X; Xu Z
Curr Top Med Chem; 2020; 20(16):1461-1467. PubMed ID: 31994464
[TBL] [Abstract][Full Text] [Related]
8. Anti-cancer pyrimidines in diverse scaffolds: a review of patent literature.
Kaur R; Kaur P; Sharma S; Singh G; Mehndiratta S; Bedi PM; Nepali K
Recent Pat Anticancer Drug Discov; 2015; 10(1):23-71. PubMed ID: 25230072
[TBL] [Abstract][Full Text] [Related]
9. Azole-Pyrimidine Hybrid Anticancer Agents: A Review of Molecular Structure, Structure Activity Relationship, and Molecular Docking.
Eze CC; Ezeokonkwo AM; Ugwu ID; Eze UF; Onyeyilim EL; Attah IS; Okonkwo IV
Anticancer Agents Med Chem; 2022 Aug; 22(16):2822-2851. PubMed ID: 35306990
[TBL] [Abstract][Full Text] [Related]
10. Triazole-fused pyrimidines in target-based anticancer drug discovery.
Dai XJ; Xue LP; Ji SK; Zhou Y; Gao Y; Zheng YC; Liu HM; Liu HM
Eur J Med Chem; 2023 Mar; 249():115101. PubMed ID: 36724635
[TBL] [Abstract][Full Text] [Related]
11. Pyrimidine-fused Derivatives: Synthetic Strategies and Medicinal Attributes.
Joshi G; Nayyar H; Alex JM; Vishwakarma GS; Mittal S; Kumar R
Curr Top Med Chem; 2016; 16(28):3175-3210. PubMed ID: 27150371
[TBL] [Abstract][Full Text] [Related]
12. Current status of carbazole hybrids as anticancer agents.
Wang G; Sun S; Guo H
Eur J Med Chem; 2022 Feb; 229():113999. PubMed ID: 34838335
[TBL] [Abstract][Full Text] [Related]
13. Current Scenario of Acridine Hybrids with Anticancer Potential.
Zhang Q; Yu X
Curr Top Med Chem; 2021; 21(19):1773-1786. PubMed ID: 34348622
[TBL] [Abstract][Full Text] [Related]
14. Current development of pyrazole-azole hybrids with anticancer potential.
Zhang S; Ye Y; Zhang Q; Luo Y; Wang ZC; Wu YZ; Zhang XP; Yi C
Future Med Chem; 2023 Aug; 15(16):1527-1548. PubMed ID: 37610862
[TBL] [Abstract][Full Text] [Related]
15. Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency.
Pan Y; Hou H; Zhou B; Gao J; Gao F
Eur J Med Chem; 2023 Dec; 262():115879. PubMed ID: 37875056
[TBL] [Abstract][Full Text] [Related]
16. Recent updates on 1,2,3-, 1,2,4-, and 1,3,5-triazine hybrids (2017-present): The anticancer activity, structure-activity relationships, and mechanisms of action.
Dong G; Jiang Y; Zhang F; Zhu F; Liu J; Xu Z
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200479. PubMed ID: 36372519
[TBL] [Abstract][Full Text] [Related]
17. Synthetic and Medicinal Perspective of Fused-Thiazoles as Anticancer Agents.
Pawar S; Kumar K; Gupta MK; Rawal RK
Anticancer Agents Med Chem; 2021; 21(11):1379-1402. PubMed ID: 32723259
[TBL] [Abstract][Full Text] [Related]
18. Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors.
Jadhav M; Sankhe K; Bhandare RR; Edis Z; Bloukh SH; Khan TA
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500603
[TBL] [Abstract][Full Text] [Related]
19. An Appraisal on Synthetic and Medicinal Aspects of Fused Pyrimidines as Anti Neoplastic Agents.
Rani I; Kaur N; Goyal A; Sharma M
Anticancer Agents Med Chem; 2023; 23(5):525-561. PubMed ID: 35786337
[TBL] [Abstract][Full Text] [Related]
20. Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-
Baillache DJ; Unciti-Broceta A
RSC Med Chem; 2020 Oct; 11(10):1112-1135. PubMed ID: 33479617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
